Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax - Wikidata - wikimedia - TriplyDB

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

http://www.wikidata.org/entity/Q34334451

about

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?Anti-infective immunoadhesins from plants.Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective Antigen Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy Antitoxin Treatment of Inhalation Anthrax: A Systematic Review Interferon protects mice against inhalation anthrax Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system Anthrax vaccination strategies Monoclonal antibody therapies against anthrax Antibodies for biodefense Peptide inhibitors MAP the way towards fighting anthrax pathogenesis.Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge Novel inhibitors of anthrax edema factor.Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax.Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor.Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen Coxiella burnetii.Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.Antibacterial role for natural killer cells in host defense to Bacillus anthracis.Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.Medical applications of leukocyte surface molecules--the CD molecules Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.In vivo efficacy of beta-cyclodextrin derivatives against anthrax lethal toxin Pathology and pathophysiology of inhalational anthrax in a guinea pig model.New insights into the pathogenesis and treatment of anthrax toxin-induced shock.Bacillus anthracis: interactions with the host and establishment of inhalational anthrax.Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.Controlled release of an anthrax toxin-neutralizing antibody from hydrolytically degradable polyethylene glycol hydrogels Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits.The physiologic responses of Dutch belted rabbits infected with inhalational anthrax

P2860

Q24682011-850BD94A-068E-4655-BC5F-4343E91DAF15 Q26748155-594692B2-646E-4AFF-AD05-2FCFCC7A6B04 Q26799080-CFA2D160-F1D9-417D-93BF-A8E3225B7DF5 Q27654632-612C716F-B88E-4A95-8C6C-CC83F8FB46C2 Q28383094-30ECF3BF-E562-4346-A78E-5C05819E79C2 Q28383765-DC330479-50AD-4AD9-BC90-7CD454522984 Q28384715-AABF8492-873B-415E-B799-03B0D0B37581 Q28387882-3F563B48-47AD-401F-A199-301C48F4207E Q28388590-F0E1E5BE-7DD8-484A-AC03-283B279E1478 Q28388913-D44FB074-BEB9-41B4-A8E4-E04942BC8BD8 Q28392248-9F1FCD11-64A3-4897-88B8-0CAEE169B8D7 Q28393072-0FC5C329-55BC-4F24-9AA4-71A71D0F0B81 Q28394941-DDD85365-BA7D-4F28-8ECD-17561955F0E0 Q33236706-6928C9F6-99C9-47AB-A705-1C4AE812F56A Q33258307-D3331D50-CC17-4A09-9F43-7D7984437CBF Q33284583-443417E3-AEC6-4D45-A173-B91794CE84D3 Q33351165-F9A935E2-6141-44E6-920A-88D29D1937C8 Q33783323-CBEF543F-F4C6-4E8D-A0D5-FB3399F34461 Q33936452-BEC97A62-96C3-4E76-8E45-BD5D7DEEAFF6 Q34194627-638B2DBD-97C2-4734-98E5-E9297D4E1A21 Q34289924-793D75C2-58B2-40AB-BA8D-2CBF323AE269 Q34368520-E33EB51F-EBFE-4EE0-B747-97E110CD0291 Q34483688-FF5CB11B-2C16-46D4-9EF4-947E0A96EE1B Q34497668-2BC4B363-DDCD-4E25-86EC-684BFF9A8F7D Q34596111-FADC1A8B-755B-497F-A64B-FBF641D3EFA1 Q35073821-2132DCE6-D353-4242-9901-D3A2D6BA315C Q35665363-B5793154-ECD4-43D2-BC1D-7CB09B2AC864 Q35666215-1FEB145A-3A84-4678-AA4B-1EDA4C227623 Q35690889-8C0390E8-0FA9-4E9F-BECB-17A9285B8610 Q36539626-E2540D25-DE54-40AE-8363-38C02CB8A621 Q36646741-4CEEDF19-38A6-4ADD-9DD1-D749DFB8A19B Q36703020-070475B8-AC79-4101-B0A6-F73532E93F64 Q36804713-CD1EC96A-55A1-478D-9F73-3A146CB0C60C Q36842720-BA97D180-2C64-4782-903A-989BB55C884D Q36895609-4C937864-9A1E-4866-9C69-06A364CD5F34 Q36901955-5258A017-5822-429B-991E-70CC1875913E Q37065380-FF6A83C5-BBEF-40C3-B40E-45AE46EF6B2E Q37262118-AC5DEF75-2DA8-4B2D-8503-D9F4DF4074F8 Q37263339-239E4BBA-CAA1-4117-93DA-991BDBE34767 Q37322409-20BC43FA-7A6B-48DF-8A93-6037DC9B8ACE

P2860

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

http://www.wikidata.org/entity/Q34334451

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@ast

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@en

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@nl

type

label

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@ast

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@en

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@nl

prefLabel

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@ast

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@en

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@nl

P1433

Q34334451-C3F46D92-9238-42D4-95A4-13E3CCECA3FA

P1476

Q34334451-BBF3B1C8-D6C0-4894-B915-BE1D0D51F016

P2093

Q34334451-1B33E67F-CB3D-4741-8DE6-76A602AEB245

Q34334451-296CD04F-56DC-41E8-963B-6A88A92E9483

Q34334451-311057C5-CFCD-46C4-9121-BEBF3FF99B41

Q34334451-7076CB3D-3567-4B75-AEE3-75B8DC0E4D6B

Q34334451-742BD5E7-784E-42F9-A55C-AA256565AA5C

Q34334451-78EC58E3-CD9D-4A40-9809-88B14F84FE1E

Q34334451-92510F24-CA72-4E1C-A49B-C6B2C248F2E7

Q34334451-92819C5A-3B28-4FE7-959C-C64EC05EE0C8

Q34334451-C11315ED-7237-443D-8196-44C405B74E64

Q34334451-C914C983-E4E3-4322-B5A7-F2C7E68A8070

P2860

Q34334451-0514E270-7267-4399-A05B-E7EF53F93AB2

Q34334451-14F163B7-4E2E-47F3-9F38-41B576B4309F

Q34334451-1D902A03-B9CC-4303-8337-D57E4A56004D

Q34334451-21EBC99D-BA28-4023-88EE-F616FE8A41AE

Q34334451-23905E77-2CFB-400F-B9FC-D5A0CDB71EDA

Q34334451-24E23784-5201-463B-B64B-D90471348372

Q34334451-38270F37-1CFB-454C-9B83-AA979C7ECEDB

Q34334451-391DDC39-E6E1-4BBE-AD66-15B14B4CB1B8

Q34334451-4099B406-2101-469D-A17D-7A83955A81A0

Q34334451-4208E45F-0B80-4E9F-BCF7-E82B14D81A73

P304

Q34334451-2FEC8042-E639-47A3-87AA-7677876A6D62

P31

Q34334451-06FC5E9D-BC51-48F2-AAF4-0357255E7D1B

P356

Q34334451-AB2DB966-9093-4BD4-A904-B4C7052460C0

P407

Q34334451-5AC61B21-3E1F-4A4B-BB05-6D0B0D42D287

P433

Q34334451-3D7BA281-88B8-4917-A331-282CEA9F5EAD

P478

Q34334451-FE7A2178-3D88-47F4-AF6A-1845FE206E7C

P577

Q34334451-FB115AF4-5E26-4BE2-9712-1C3D94EB77D6

P5875

Q34334451-F47FB235-0360-4492-943A-6BA6F1346C9F

P698

Q34334451-03598E62-E72A-4135-84AA-739BE4023306

P921

Q34334451-839B34B8-0476-4B49-9C19-624B5BFE43AB

P932

Q34334451-6A491A57-E0FD-4D14-BC86-AF9934EBF414

P356

IAI.74.2.1016-1024.2006

P1433

Infection and Immunity

P1476

Human monoclonal anti-protecti ...... igs against inhalation anthrax

@en

P2093

Angray S Kang

http://www.w3.org/2001/XMLSchema#string

Ashok K Chopra

http://www.w3.org/2001/XMLSchema#string

Autumn Wenglikowski

http://www.w3.org/2001/XMLSchema#string

Bagram M Chatuev

http://www.w3.org/2001/XMLSchema#string

David M Noffsinger

http://www.w3.org/2001/XMLSchema#string

Jagadish Sircar

http://www.w3.org/2001/XMLSchema#string

Jason E Comer

http://www.w3.org/2001/XMLSchema#string

Johnny W Peterson

http://www.w3.org/2001/XMLSchema#string

Kristin G Walberg

http://www.w3.org/2001/XMLSchema#string

Lawrence R Stanberry

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a complex between anthrax toxin and its host cell receptor

Crystal structure of the von Willebrand factor A domain of human capillary morphogenesis protein 2: an anthrax toxin receptor

Contribution of individual toxin components to virulence of Bacillus anthracis

Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed

Quantitative pathology of inhalational anthrax I: quantitative microscopic findings

ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection

Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility

Pathology and pathogenesis of bioterrorism-related inhalational anthrax

Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

P304

1016-1024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.74.2.1016-1024.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7343706

http://www.w3.org/2001/XMLSchema#string

P698

16428748

http://www.w3.org/2001/XMLSchema#string

P921

P932

1360364

http://www.w3.org/2001/XMLSchema#string